← All trials
NCT07120698
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2025
- Primary completion
- Jun 26, 2029
- Completion date
- Jul 26, 2029
- First posted
- Aug 13, 2025
- Last posted
- Aug 13, 2025
- Enrollment
- 115
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangdong Association of Clinical TrialsLead sponsor
- Shantou UniversityCollaborator
- Suining Central HospitalCollaborator
- Guangdong Association of Clinical TrialsSponsor investigator
- Guangdong Association of Clinical TrialsOfficial
- Zunyi Medical CollegeCollaborator
- China Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.